Actively Recruiting
Nebulized Ketamine Compared to Placebo Plus Standard Care for Adults with Moderate to Severe Asthma Attacks in the Emergency Department
Led by Oman Medical Speciality Board · Updated on 2026-10-19
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether nebulized ketamine can help improve breathing during moderate to severe asthma attacks in adults treated in the emergency department. This Phase 2 clinical trial aims to compare the effects and safety of inhaled ketamine versus a placebo when added to standard asthma treatments. The goal is to see if ketamine improves lung function and to identify any side effects from inhaled administration. Participants will receive either a single dose of nebulized ketamine at 0.5 mgkg diluted in saline or a placebo nebulization of saline alone. Both treatments are given after standard emergency asthma care, which includes inhaled bronchodilators, corticosteroids, and oxygen as needed. The nebulized medication is delivered via a standard jet nebulizer, and participants are monitored continuously for 60 minutes after administration. During the study, participants will have their breathing measured using a peak expiratory flow meter before treatment, at 30 minutes, and 60 minutes after. Researchers will also observe symptoms, vital signs, and any side effects throughout monitoring. Additional outcomes such as the need for intensive treatments, hospital admissions, and changes in breathing difficulty will be recorded. The study will continue until August 2029, assessing both the lung function changes and safety profile of nebulized ketamine in this emergency setting.
CONDITIONS
Brief Title
Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here